Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Grommes

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2021
Prognostic value of [<sup>18</sup>F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapiesSimone Krebs, Audrey Mauguen, Onur Yildirim, et al.
Leukemia & Lymphoma|June 15, 2023
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System LymphomaChristian Grommes, Elena Pentsova, Lauren R Schaff, et al.
Neuro-Oncology|August 26, 2011
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerChristian Grommes, Geoffrey R Oxnard, Mark G Kris, et al.
Neuro-Oncology|June 25, 2024
Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020Kathryn R Tringale, Michael Scordo, Joachim Yahalom, et al.
Blood Advances|August 21, 2024
Evolving consolidation patterns and outcomes for a large cohort of patients with primary CNS lymphomaKathryn R Tringale, Michael Scordo, Joachim Yahalom, et al.
Future Oncology (London, England)|June 19, 2026
IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphomaLakshmi Nayak, Christian Grommes, Charles Psoinos, et al.
Journal of Neuro-Oncology|August 4, 2018
Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphomaVaios Hatzoglou, Jung Hun Oh, Olivia Buck, et al.
Nature Reviews. Disease Primers|June 15, 2023
Primary central nervous system lymphomaAndrés J M Ferreri, Teresa Calimeri, Kate Cwynarski, et al.
Neurology|August 10, 2022
Combination Olaparib and Temozolomide for the Treatment of Glioma: A Retrospective Case SeriesLauren R Schaff, Marina Kushnirsky, Andrew L Lin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 9, 2021
[<sup>89</sup>Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendrogliomaSimone Krebs, Christian Grommes, Michael R McDevitt, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2021
Prognostic value of [<sup>18</sup>F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapiesSimone Krebs, Audrey Mauguen, Onur Yildirim, et al.
Leukemia & Lymphoma|June 15, 2023
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System LymphomaChristian Grommes, Elena Pentsova, Lauren R Schaff, et al.
Neuro-Oncology|August 26, 2011
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerChristian Grommes, Geoffrey R Oxnard, Mark G Kris, et al.
Neuro-Oncology|June 25, 2024
Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020Kathryn R Tringale, Michael Scordo, Joachim Yahalom, et al.
Blood Advances|August 21, 2024
Evolving consolidation patterns and outcomes for a large cohort of patients with primary CNS lymphomaKathryn R Tringale, Michael Scordo, Joachim Yahalom, et al.
Future Oncology (London, England)|June 19, 2026
IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphomaLakshmi Nayak, Christian Grommes, Charles Psoinos, et al.
Journal of Neuro-Oncology|August 4, 2018
Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphomaVaios Hatzoglou, Jung Hun Oh, Olivia Buck, et al.
Nature Reviews. Disease Primers|June 15, 2023
Primary central nervous system lymphomaAndrés J M Ferreri, Teresa Calimeri, Kate Cwynarski, et al.
Neurology|August 10, 2022
Combination Olaparib and Temozolomide for the Treatment of Glioma: A Retrospective Case SeriesLauren R Schaff, Marina Kushnirsky, Andrew L Lin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 9, 2021
[<sup>89</sup>Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendrogliomaSimone Krebs, Christian Grommes, Michael R McDevitt, et al.
Pageof 10